Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
NTI
vs
S
S&P/ASX 300
NTI
Over the past 12 months, NTI has underperformed S&P/ASX 300, delivering a return of -6% compared to S&P/ASX 300's 1% drop.
Stocks Performance
NTI vs S&P/ASX 300
Performance Gap
NTI vs S&P/ASX 300
Performance By Year
NTI vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Neurotech International Ltd
Glance View
Neurotech International is an Australian life sciences company focused on treatments for neurological and neurodevelopmental disorders. It develops medicines and health products aimed at conditions such as autism spectrum disorder and other brain-related illnesses, with much of its work centered on cannabinoid-based formulations and related clinical research. The company’s customers are mainly patients, families, doctors, and specialty health providers who use or prescribe its products, along with partners it works with on development and distribution. Neurotech makes money through product sales where its therapies are commercialized, and it can also earn income from licensing, partnerships, and related development agreements as its medicines move through testing and commercialization. What makes Neurotech’s business model different is that it sits between biotech research and healthcare products. It is not a broad drugmaker selling many medicines; instead, it is focused on a narrow set of neurological conditions where it tries to turn specialized research into targeted treatments that can be sold through medical channels.